Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis
Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis
Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.
Patients with NASH to receive the treatment versus placebo for 40 weeks followed by a liver biopsy.
Inclusion Criteria:
Exclusion Criteria: